[Federal Register Volume 77, Number 210 (Tuesday, October 30, 2012)]
[Notices]
[Page 65693]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-26635]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2012-N-0001]


Cellular, Tissue and Gene Therapies Advisory Committee; Amendment 
of Notice

AGENCY:  Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of a meeting of the Cellular, Tissue and Gene Therapies 
Advisory Committee. This meeting was announced in the Federal Register 
of October 17, 2012 (77 FR 63840-63841). The amendment is being made to 
reflect a change in the Date and Time, Agenda, Procedure, and Closed 
Committee Deliberations portions of the document. There are no other 
changes.

FOR FURTHER INFORMATION CONTACT:  Gail Dapolito or Sheryl Clark, Center 
for Biologics Evaluation and Research (HFM-71), Food and Drug 
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, 
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington DC area). Please call the Information Line for 
up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION:  In the Federal Register of October 17, 
2012, FDA announced that a meeting of the Cellular, Tissue and Gene 
Therapies Advisory Committee would be held on November 29, 2012. On 
page 63841, in the first column, the Date and Time portion of the 
document is changed to read as follows:
    The teleconference meeting will be held on November 29, 2012 from 1 
p.m. to 4:30 p.m., Eastern Time.
    On page 63841, in the first column, last paragraph, the Agenda 
portion is changed to read as follows:
    On November 29, 2012 the committee will meet in open session to 
hear updates of research programs in the Gene Transfer and 
Immunogenicity Branch, Office of Cellular, Tissue and Gene Therapies, 
Center for Biologics Evaluation and Research, FDA.
    On page 63841, second column, second paragraph, first sentence, the 
Procedure portion is changed to read as follows:
    On November 29, 2012, from 1 p.m. to 2:30 p.m. (Eastern Time) the 
meeting is open to the public.
    On page 63841, second column, second paragraph, fourth sentence, 
the Procedure portion is changed to read as follows:
    Oral presentations from the public will be scheduled between 
approximately 2:30 p.m. and 3:30 p.m.
    On page 63841, second column, third paragraph, first sentence, the 
Closed Committee Deliberations portion is changed to read as follows:
    On November 29, 2012 from approximately 3:30 p.m. to 4:30 p.m., the 
meeting will be closed to permit discussion where disclosure would 
constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 
552b(c)(6)).
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: October 23, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-26635 Filed 10-29-12; 8:45 am]
BILLING CODE 4160-01-P